No Data
Express News | 【Change Report】Mr. Sakae Okano reported a decrease in his shareholding of Keifarma (4896.JP) to 11.05%.
CellSeed - temporarily reached the upper limit, with a rapid rise in Qualisys expanding interest in drug discovery-related stocks.
The stock reached a temporary high. Qualips <4894> announced its application for manufacturing and selling regenerative medicine products derived from iPS cell-derived cardiac muscle cell sheets, which has led to a surge in buying interest, reaching a stop-high buying indication, expanding into drug discovery-related stocks. Besides Cellseed, K Pharma <4896> and Heartseed <219A> are also rapidly rising. Cellseed disclosed the start of clinical trials for allogenic cartilage cell sheets on March 24, which seems to be attracting renewed buying interest.
Stock News Premium = The Growth Market will be (Delisted) for stocks with a Market Cap of less than 10 billion yen.
＜Currently, 70% of the stocks are affected, and the impact extends to IPOs＞ The Tokyo Stock Exchange has tightened the listing maintenance standards for the Growth Market and plans to delist companies that have not reached a Market Cap of 10 billion yen after five years of listing starting in 2030. Although there is still time until the deadline, 70% of the 612 listed stocks have a Market Cap of less than 10 billion yen, and the Emerging Markets, including IPOs, will enter a period of significant transformation. It has been noted that companies showcase impressive growth rates during their IPOs but deteriorate post-listing.
Express News | [Change Report] SBI Investment reports that the Shareholding percentage of Kepharma (4896.JP) has decreased to 15.1%.
Express News | [Change Report] SBI Investment reported a decrease in Shareholding of Kepharma (4896.JP) to 17.08%.
Express News | [Change Report] Itochu Technology Ventures reports a decrease in Shareholding of Keipharma (4896.JP) to 2.02%.
